SCIENCE 37 HOLDINGS INC (SNCE) Stock News
NASDAQ:SNCE - Nasdaq - US8086442071 - Common Stock - Currency: USD
SNCE Latest News, Press Relases and Analysis
Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures....
eMed commences tender offer for Science 37
/PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has...
SNCE Stock Earnings: Science 37 Hldgs Beats EPS, Beats Revenue for Q1 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Science 37 Hldgs (NASDAQ:SNCE) just reported results for the first quarter of 2...
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials
Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials....
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities....
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study....
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA Inspection
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program....
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial....
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burden
eMed completes tender offer for all outstanding shares of Science 37
/PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin...
Shareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMed
/PRNewswire/ -- Ademi LLP is investigating Science 37 (Nasdaq: SNCE) for possible breaches of fiduciary duty and other violations of law in its transaction...
Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up 0.03% to 38,121.11 while the NASDAQ rose 0.48% to 15,529.84. The S&P 500 also rose, gaining, 0.19% to 4,900.27.
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped 65.5% to $1.47 on Monday.
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 stockholders to receive $5.75 per share in cash...
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 stockholders to receive $5.75 per share in cash